AI Verdict
REGN has stronger fundamentals based on our AI analysis.
ABT vs REGN Fundamental Comparison
| Metric | ABT | REGN |
|---|---|---|
| Revenue | $44.3B | $14.3B |
| Net Income | $6.5B | $4.5B |
| Net Margin | 14.7% | 31.4% |
| ROE | 12.5% | 14.4% |
| ROA | 7.5% | 11.1% |
| Current Ratio | 1.58x | 4.13x |
| Debt/Equity | 0.25x | 0.06x |
| EPS | $3.72 | $41.48 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
ABT vs REGN: Frequently Asked Questions
Is ABT or REGN a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), REGN has stronger fundamentals. ABT is rated BUY (77% confidence) while REGN is rated BUY (80% confidence). This is not investment advice.
How does ABT compare to REGN fundamentally?
ABBOTT LABORATORIES has ROE of 12.5% vs REGENERON PHARMACEUTICALS, INC.'s 14.4%. Net margins are 14.7% vs 31.4% respectively.
Which stock pays higher dividends, ABT or REGN?
ABT has a dividend yield of N/A or no dividend while REGN has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in ABT or REGN for long term?
For long-term investing, consider that ABT has BUY rating with 77% confidence, while REGN has BUY rating with 80% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about ABT vs REGN?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For ABT vs REGN, the AI consensus favors REGN based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.